Holen Sie sich die Stockscreener-App
1.75
4.79%
0.08
Vorhandelsmarkt:
1.74
-0.01
-0.57%
Schlusskurs vom Vortag:
$1.67
Offen:
$1.69
24-Stunden-Volumen:
1.15M
Relative Volume:
0.56
Marktkapitalisierung:
$159.02M
Einnahmen:
$70.39M
Nettoeinkommen (Verlust:
$-43.97M
KGV:
-3.3777
EPS:
-0.5181
Netto-Cashflow:
$-23.85M
1W Leistung:
+19.05%
1M Leistung:
+56.25%
6M Leistung:
-27.08%
1J Leistung:
-40.48%
1-Tages-Spanne:
$1.69
$1.7893
1-Wochen-Bereich:
$1.42
$1.7893
52-Wochen-Spanne:
$0.9583
$3.87
Codexis Inc Stock (CDXS) Company Profile
Firmenname
Codexis Inc
Sektor
Branche
Telefon
650-421-8100
Adresse
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
1.75 | 151.75M | 70.39M | -43.97M | -23.85M | -0.5181 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-19 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-29 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-07 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-08-07 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2021-04-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-03-01 | Eingeleitet | Stifel | Buy |
| 2021-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-10 | Eingeleitet | The Benchmark Company | Buy |
| 2019-01-17 | Hochstufung | First Analysis Sec | Neutral → Outperform |
| 2018-05-16 | Eingeleitet | Stephens | Overweight |
| 2017-10-13 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-31 | Eingeleitet | Jefferies | Buy |
| 2017-01-26 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-01-04 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2016-01-06 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Codexis Inc Aktie (CDXS) Neueste Nachrichten
Analyst sentiment unchanged after Codexis (CDXS) earnings - MSN
Analyst Sentiment Unchanged After Codexis (CDXS) Earnings - Insider Monkey
Codexis rises after Q4 beat, strong outlook - MSN
Benchmark reiterates Hold on Codexis stock after Q4 results By Investing.com - Investing.com India
Benchmark reiterates Hold on Codexis stock after Q4 results - Investing.com
Four Stocks at the Intersection of Enzymes, Longevity, and the $400 Billion Wellness Boom (CELV, NAGE, MTEX, CDXS) - marketscreener.com
Why did Codexis (CDXS) stock soar nearly 38% after hours? - MSN
Biocatalysis Market Accelerates with Rising Demand - openPR.com
Jobs Data: Does Codexis Inc offer margin of safety2026 Weekly Recap & Risk Controlled Swing Alerts - baoquankhu1.vn
CDXS Stock Price, Quote & Chart | CODEXIS INC (NASDAQ:CDXS) - ChartMill
Fund Flows: Is Codexis Inc stock technically oversold2026 Chart Watch & Weekly High Return Stock Opportunities - baoquankhu1.vn
Biocatalysis and Biocatalysts Market is expected to Hit US$ 6.7 - openPR.com
Codexis (CDXS) beats Q4 earnings and revenue estimates - MSN
Codexis (CDXS) Is Up 30.9% After Merck-Fueled Q4 Profit Beat And 2026 Revenue GuidanceHas The Bull Case Changed? - simplywall.st
Short Interest in Codexis, Inc. (NASDAQ:CDXS) Grows By 26.2% - MarketBeat
Codexis (CDXS) Is Up 30.9% After Returning To Q4 Profitability And Issuing 2026 Revenue Guidance - Yahoo Finance
Codexis Faces Strategic Challenges Amidst Revenue Dip - timothysykes.com
Assessing Codexis (CDXS) Valuation After Strong Earnings And New ECO Synthesis siRNA Agreement - simplywall.st
Codexis (NASDAQ:CDXS) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year - AOL.com
Codexis Stock Plummets Amid Financial Struggles - StocksToTrade
Why did CDXS stock jump 7% today? - MSN
Cantor Fitzgerald Maintains Overweight on Codexis (CDXS) March 2026 - Meyka
Codexis (CDXS) Q4 Profit Turns Positive EPS Into Test Of Turnaround Narrative - Sahm
Dow Tumbles Over 1%; US Weekly Jobless Claims Fall - Sahm
Why Did Codexis (CDXS) Stock Soar Nearly 38% After Hours? - Sahm
Crude Oil Surges Over 8%; Dollar General Shares Fall After Q4 Results - Sahm
Codexis (CDXS) Stock Jumps 2.4% Following Strong Q4 Earnings Report - MEXC
Stifel reiterates Codexis stock Buy rating on solid 2026 guidance - Investing.com UK
Cantor Fitzgerald reiterates Codexis stock rating on siRNA deal By Investing.com - Investing.com South Africa
Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform (NASDAQ:CDXS) - Seeking Alpha
Codexis (CDXS) Stock Rises 2.4% After Q4 Earnings Beat - MEXC
Stifel reiterates Codexis stock Buy rating on solid 2026 guidance By Investing.com - Investing.com India
Codexis Shines as Q4 Profit Sparks Investor Enthusiasm - StocksToTrade
Cantor Fitzgerald reiterates Codexis stock rating on siRNA deal - Investing.com
Codexis Surpasses Q4 Expectations, Stock Price Volatility Anticipated - timothysykes.com
Codexis (CDXS) Q4 2025 Earnings Call Transcript - AOL.com
Codexis stock jumps on Q4 earnings beat, strong 2026 outlook - National Today
Finanzdaten der Codexis Inc-Aktie (CDXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):